PRNewsWire · PINC · November 4, 2026
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: PRNewsWire ↗